NEW YORK, Oct. 2, 2012 /PRNewswire/ -- Immunovaccine Inc.,
(TSX-V: IMV), a clinical stage vaccine company, announced that
John Trizzino, chief executive
officer and director, will present at
RetailInvestorConferences.com.
DATE: October 4,
2012
TIME: 10:00 AM
EDT
LINK:
www.retailinvestorconferences.com > red "register / watch event
now" button
This will be a live, interactive online event where investors
are invited to ask the company questions in real-time - both in the
presentation hall and the company's "virtual trade booth." If
attendees are not able to join the event live on the day of the
conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register to save time and
receive event updates.
About Immunovaccine Inc.
Immunovaccine Inc. (TSX-V: IMV) applies its novel adjuvanting
platform to the development of vaccines for cancer therapy,
infectious diseases and animal health. The Company's DepoVax™
platform is a patented formulation that provides controlled and
prolonged exposure of antigens plus adjuvant to the immune system.
Immunovaccine has advanced two DepoVax-based cancer vaccines into
Phase I human clinical trials. The Company is also advancing a
broad infectious disease pipeline including vaccines in such
indications as malaria, respiratory syncytial virus (RSV) and
anthrax. In addition to the Company's human health vaccine
strategy, it continues to capture value from animal health vaccine
applications. Immunovaccine has key partnerships in the animal
health sector including an agreement with PfizerAnimal
Health.
About RetailInvestorConferences.com
Since 2010, RetailInvestorConferences.com, created by
BetterInvesting (NAIC), PR Newswire and MUNCmedia, has
been the only monthly virtual investor conference series that
provides an interactive forum for presenting companies to meet
directly with retail investors using a graphically-enhanced online
platform.
Designed to replicate the look and feel of location-based
investor conferences, Retail Investor Conferences unites PR
Newswire's leading-edge online conferencing and investor
communications capabilities with BetterInvesting's extensive retail
investor audience network and MUNCmedia's sophisticated retail
investor targeting.
SOURCE Immunovaccine Inc.